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Background: Dystonia and ataxia are manifestations of numerous disorders, and 
indeed, an ever-expanding spectrum of genes causing diseases that encompass 
dystonia and ataxia are discovered with the advances of genetic techniques. In 
recent years, a pathophysiological link between both clinical features and the role of 
the cerebellum in the genesis of dystonia, in some cases, has been proposed. In 
clinical practice, the genetic diagnosis of dystonia-ataxia syndromes is a major issue 
for genetic counseling, prognosis and, occasionally, specific treatment.  
Methods: For this pragmatic and educational review, we conducted a 
comprehensive and structured literature search in Pubmed, OMIM and 
GeneReviews using the key words “dystonia” and “ataxia” to identify those genetic 
diseases that may combine dystonia with ataxia. 
Results: There is a plethora of genetic diseases causing dystonia and ataxia. We 
propose a series of clinico-radiological algorithms to guide their differential diagnosis 
depending on the age of onset, additional neurological or systemic features and 
imaging findings. We suggest a sequential diagnostic approach to dystonia-ataxia 
syndromes. We briefly highlight the pathophysiological links between dystonia and 
ataxia and conclude with a review of specific treatment implications.  
Conclusion: The clinical approach presented in this review is intended to improve 
diagnostic success of clinicians when facing with patients with dystonia-ataxia 
syndromes.   




Dystonia is characterized by “sustained or intermittent muscle contractions causing 
abnormal, often repetitive, movements, postures, or both”1. It can be the 
manifestation of a plethora of diseases, and indeed, with the advances of genetic 
techniques, we recognize an ever-expanding spectrum of genes causing various 
dystonia syndromes2. For clinical practice, the new classification of dystonia fosters a 
phenomenological approach with categorization according to recognizable common 
associations, which allows narrowing down the differential diagnosis1. Such 
associations are for example the combined dystonia syndromes like dystonia-
myoclonus and dystonia-parkinsonism, with well-described differential diagnoses3. In 
contrast, scarce information exists about the combination of dystonia and ataxia. 
Interestingly, there is also pathophysiological link between both phenotypes and the 
role of the cerebellum in the genesis of dystonia has been the focus of research 
lately4-6. Based on a broad and exhaustive literature review we here review the 
spectrum of disorders that can present with dystonia and ataxia, and propose a 
clinico-radiological diagnostic algorithm. We examine existing evidence regarding 




We conducted a comprehensive and structured search in Pubmed, OMIM and 
GeneReviews using the key words “dystonia” and “ataxia” to identify those genetic 
diseases that may combine dystonia with ataxia. Publications written in English and 
Spanish and published up to December 31, 2017 were reviewed.  
 
This article is protected by copyright. All rights reserved.
5 
 
Diagnostic approach to genetic causes of dystonia-ataxia 
There is a plethora of more than 100 genetic disorders giving rise to dystonia-ataxia 
syndromes. In clinical practice, when evaluating patients with dystonia-ataxia, the 
differential diagnosis can be largely guided by the age of onset, additional 
neurological or systemic features and radiological findings. Clinical diagnostic 
algorithms that take into account the presence or absence of additional clinical clues 
and relevant complementary studies are illustrated in Figure 1(infancy/childhood 
onset) and Figure 2 (adulthood onset). For didactic purposes, both figures include 
disorders that are most prevalent or relevant from a therapeutic perspective and 
which therefore should be suspected first, according to authors’ opinion. Table 1 
provides a more comprehensive list of differential diagnoses. Entities where dystonia 
and ataxia are prominent and frequent features are considered first, before thinking 
of disorders where the combination of dystonia and ataxia is found only occasionally. 
A comprehensive summary of all diseases in which dystonia and ataxia were 
reported with their respective clinical features and relevant complementary studies is 
presented according to mode of inheritance in Supplementary Table 1. Sometimes, 
there are certain clinical clues (“red flags”), which can guide the differential 
diagnostic considerations (Table 2) and should therefore not be missed. Similarly, 
imaging findings are often helpful in directing further diagnostic evaluations (Figure 
3). 
 
Dystonia and ataxia may develop during the disease course sequentially, or in rare 
cases, simultaneously. Interestingly, some disorders that usually present with 
specific features, like ataxia in ataxia-telangiectasia, can also have a very different 
clinical picture, with isolated or predominant dystonia without ataxia7,8. In line with 
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this, some complex phenotypic disorders may initially mimic isolated dystonia before 
other clinical characteristics become evident, e.g. in Wilson´s disease or in several 
spinocerebellar ataxias9,10.  
 
Different types or forms of dystonia were described in the genetic diseases listed: 
focal, segmental, generalized and hemidystonia (e.g. in autosomal dominant 
progressive external ophthalmoplegia type 1 due to POLG mutations11 and in Coats 
plus syndrome12) as well as task-specific dystonia (e.g. in several spinocerebellar 
ataxias10,13, mitochondrial disorders14, ataxia-telangiectasia-like disorder type 115 and 
in L-2-hydroxyglutaric aciduria16), paroxysmal or episodic dystonia (paroxysmal 
kinesigenic dyskinesia due to PRRT2 mutations17, episodic ataxia type 218 and 
biotin-thiamine-responsive basal ganglia disease due to SLC19A3 mutations19). The 
Supplementary Table 1 lists the various forms of dystonia described in genetic 
dystonia-ataxia syndromes. In some cases, dystonia can spontaneously attenuate 
over time as occurs in ataxia-oculomotor apraxia type 420,21, or is induced by 
different triggers, e.g. exercise, infections, or emotional stress (PxMD-SLC2A1 
disorders22,23, pyruvate dehydrogenase E1-alpha deficiency24,  biotin-thiamine-
responsive basal ganglia disease25). In some unusual cases, a phenotype of 
dystonia can replace or overshadow ataxia during the disease course (e.g. in ataxia 
with vitamin E deficiency26) or viceversa (SCA-CACNA1A27). Lastly, the combination 
of dystonia and ataxia often correlates with disease course or severity. For example, 
the presence of dystonia was associated with greater severity of ataxia in the 
spinocerebellar ataxias SCA-ATXN1, SCA-ATXN2, and SCA-ATXN328. In line with 
this observation, SCA-ATXN2 and SCA-ATXN3 patients with dystonia showed 
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greater CAG repeat expansion28,29. In contrast, dystonia was associated a slower 
progression in SCA-CACNA1A29.  
 
Diagnostic management.  
After careful clinical examination, MR imaging is essential as the presence or 
absence of cerebellar atrophy and other structural abnormalities will crucially guide 
differential diagnostic considerations. An initial screening of certain biochemical 
markers would depend on age of onset and clinical suspicion, but should always 
include serum copper and ceruloplasmin (plus 24h urinary copper excretion 
depending on the level of probability). Other parameters in peripheral blood useful to 
screen for more common conditions with specific treatment implications include 
vitamin E levels (ataxia with vitamin E deficiency), glucocerebrosidase enzyme 
activity in leukocytes (reduced in Gaucher disease), and triol levels (elevated in 
Niemann-Pick disease type C). If the differential diagnosis includes ataxia 
teleangiectasia (AT) and its lookalikes, serum testing should include alpha-
fetoprotein (elevated in AT and ataxia-oculomotor apraxia type 2), immunoglobulin 
levels (often reduced in AT), albumin (reduced in ataxia-oculomotor apraxia type 1), 
and cholesterol (increased in ataxia-oculomotor apraxia type 1). In case of 
suspected glucose transporter type 1 deficiency syndrome, serum and CSF should 
be tested for the glucose levels (CSF glucose concentration <60 mg/dL) and its ratio 
(<0.4). If these tests were negative, genetic testing of most frequent causes of 
dystonia-ataxia syndromes, like Friedreich ataxia, and several spinocerebellar 
ataxias (SCA-ATN1, SCA-ATXN2, SCA-ATXN3, SCA-CACNA1A, SCA-TBP and 
SCA-ATXN1) should be explored first (again depending on clinical features and 
age). These are all disorders caused by repeat expansions and are therefore not 
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detectable by next-sequencing genetic tests. After these common causes were ruled 
out, genetic testing should be continued with whole exome sequencing or 
comprehensive dystonia and ataxia panels that include the dystonia-ataxia 
syndromes here described. 
 
The role of the cerebellar dysfunction in dystonia 
Dystonia is usually associated with dysfunction of basal ganglia circuits, rather than 
alteration of the cerebellum30. Many of the genetic diseases here reviewed, 
encompass complex phenotypes due to neurodegeneration of multiple systems and 
structures, including the alteration of both basal ganglia and cerebellum, which may 
explain the occurrence of dystonia in the setting of ataxia and other neurological 
features. There is a growing evidence of an important role of the cerebellar 
dysfunction in dystonia4-6,31-36. Animal models of generalized dystonia showed 
abnormal cerebellar activity37-39 and, dystonia can be independent of 
the basal ganglia, and can be alleviated or abolished by inactivation of the 
cerebellum40-42. Moreover, a sophisticated network approach strongly suggested that 
the molecular pathways of ataxia and dystonia are closely related43. Thus, the large 
numbers of disorders featuring both dystonia and ataxia is not too surprising. 
However, correlational studies, such as these network approaches cannot dissect 
cause and effect. 
 
Treatment 
Rehabilitation, physical, occupational and speech therapy are usually combined with 
pharmacological treatment where appropriate44,45. Unfortunately, there exists no 
medication to date that has been approved for the treatment of cerebellar ataxia or 
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that can prevent or slow down neurodegenerative processes that are not related to 
metabolic diseases, with the exception of aminopyridines and acetazolamide for 
episodic ataxia in episodic ataxia type 244. Most drugs used to treat ataxia or other 
cerebellar features failed to achieve significant and sustained improvement44,45. For 
patients with Friedreich ataxia or spinocerebellar ataxia, riluzole showed modest 
improvement in ataxia at 12 months in a Class I study46 (Supplementary Table 2). 
Careful attention should be paid to drugs that can exacerbate ataxia, such as 
alcohol, lithium, phenytoin and phenobarbital47 or factors that can precipitate 
episodic ataxia in paroxysmal kinesigenic dyskinesia and episodic ataxia type 2, like 
physical or emotional stressful situations, alcohol, fatigue or exertion. Likewise, 
drugs that are capable of exacerbating dystonic symptoms, like neuroleptics, 
piperazine derivatives with calcium antagonist properties (cinnarizine, flunarizine,) or 
antiemetics (metoclopramide), among others, should be avoided48.  
 
Disorders with specific management implications.  
Some of the genetic dystonia-ataxia syndromes are preventable by avoiding triggers 
or are treatable, either by reduction of toxic products, dietary interventions, or vitamin 
supplements49. Early diagnosis and therapy may slow or halt the clinical course, 
partially reverse symptoms or prevent their development altogether (Supplementary 
Table 2). In general, the response to treatment is more likely at early stages of the 
disease and in children than in adults.  
 
Symptomatic therapy of dystonia 
Treatment of dystonic features remains difficult. In very rare cases, they can resolve 
spontaneously and completely over time, e.g. in ataxia-oculomotor apraxia type 4 
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and SCA-CACNA1A21,27. Without counting on these exceptions, dystonic symptoms 
are always persistent and hardly alleviated with drugs, like levodopa, anticholinergics 
or botulinum toxin13,26,50-53. It is important to emphasize that botulinum toxin use can 
be dangerous in the treatment of cervical or oromandibular dystonia in patients with 
spinocerebellar ataxias, because dysphagia is very common in this group of 
neurodegenerative diseases54. In some of the genetic dystonia-ataxia syndromes, 
like SCA-ATXN2, SCA-ATXN3 and ataxia-telangiectasia, dystonic features can show 
a marked response to levodopa8,55,56 and illustrate the rationale of a trial with this 
drug10,11,13,57-59. Indeed, dopamine replacement therapy was established in 16 of 140 
(11%) patients with spinocerebellar ataxia, with a partial response in 75% of the 
cases13. Pharmacological treatment with trihexyphenidyl, baclofen, benzhexol, 
diazepam or clonazepam may also produce variable relief of dystonic postures26,60-
62. Currently, there is lack of evidence for the efficacy of non-invasive brain 
stimulation techniques, like transcranial magnetic stimulation and transcranial 
direct/alternating current stimulation in patients with dystonia63. In contrast, surgical 
interventions for dystonia such as GPi-DBS have been found effective to some 
extent in patients with Wilson disease64,65, ataxia-telangiectasia and its variant64,66, 
spinocerebellar ataxias64,67-69, episodic ataxia type 270, Cockayne syndrome71,72, 
PLA2G6-associated neurodegeneration73, and neurodegeneration with brain iron 
accumulation type 1 due to mutations in the PANK2 gene74-77. Responses are often 
transient or partial, usually in the range of 10-30% of improvement, which is far 
lesser as the benefit reported in patients with primary generalized dystonia64,76, but 
greater improvements of approximately 70% during the first years after surgery were 
also found74,75. Patients with dystonia combined with parkinsonism showed a greater 
response than those with dystonia-ataxia syndromes64. Surgical outcome seems to 
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be independent from age at surgery or duration of disease or dystonic features at 
surgery or dystonia severity64. 
 
Concluding remarks 
The dystonia-ataxia syndromes are a clinically and genetically heterogeneous group 
of disorders that hold a major diagnostic challenge for neurologists. In clinical 
practice, the etiological diagnosis of dystonia-ataxia syndromes is key in guiding 
genetic counseling, prognosis, and specific treatment in some cases49. Clinico-
radiological algorithms serve to narrow down the differential diagnosis for genetic 
testing and are crucial to avoid unnecessary complementary studies in scenarios 
where next-generation techniques are inaccessible to physicians or unaffordable to 
patients2,9,78-80. In addition, algorithms and lists of genes associated with dystonia-
ataxia syndromes may direct genetic research and are also important to assist 
molecular geneticists in the interpretation of whole exome or genome sequencing 
data to achieve high diagnostic accuracy80. For example, as more than 100 genes 
and/or genetic diseases need to be screened to diagnose dystonia-ataxia 
syndromes, clinico-radiological algorithms may facilitate the implementation of 
disease-focused gene panels or dedicated exome strategies to prioritize those genes 
that overlap between dystonia and ataxia43. Most important useful handles in guiding 
diagnosis with the herein proposed clinical algorithms for dystonia-ataxia syndromes 
include the age of disease onset, some associated clinical clues and particular 
imaging findings. However, major criticism to clinical algorithms arise on the clinical 
and genetic heterogeneity81, e.g., many entities or combined syndromes are not 
distinct conditions, but may represent a continuum between different phenotypes, as 
is the case for ATP1A3-, or PLA2G6-related disorders82-86. In addition, clinical 
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algorithms may not fit for atypical phenotypes or be useless if they are too simplistic 
or rigid, as they may delay or obstruct the identification of the underlying genetic 
cause in a determined patient80,81. In our opinion, clinical algorithms should be use 
as tools that can orient to specific disorders and can also be useful to validate 
genetic findings. The modern next-sequencing genetic tests do not eradicate the 
need for an exhaustive clinical assessment and are not extent of limitations as the 
inability to detect copy number variations or repeat expansions that cause, e.g., 
Friedreich ataxia and several spinocerebellar ataxias79,80.  
 
The list of genetic diseases that display either dystonia or ataxia or both in 
combination as dystonia-ataxia syndromes will continue to increase with the more 
widespread access to next-generation sequencing techniques. Continuous updating 
of dystonia-ataxia syndromes will be possible with online resources, such as 
GeneReviews (available at https://www.ncbi.nlm.nih.gov/books/NBK1116/) and the 
International Parkinson and Movement Disorder Society Genetic Mutation Online 
Database (available at http://www.mdsgene.org/)87. 
 
In conclusion, the clinical approach here presented is intended to improve diagnostic 
success of clinicians when facing with patients with dystonia-ataxia syndromes. 
Future perspectives resides in research that would provide a better understanding of 
the role of the cerebellum in dystonia, that in turn, may result in targeted treatment 
approaches to help both dystonia and ataxia features.  
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Legends to figures 
 
Figure 1. Clinical diagnostic algorithm for genetic dystonia-ataxia syndromes 
with infancy or childhood onset  
GLUT1: glucose transporter type 1; BG: basal ganglia; AR: autosomal recessive; 
AD: autosomal dominant. “Red flags” are shown in bold and “possible symptoms” 
are in italic type. 
 
Figure 2. Clinical diagnostic algorithm for genetic dystonia-ataxia syndromes 
with adulthood onset 
SCA: spinocerebellar ataxia type; DRPLA: dentatorubral-pallidoluysian atrophy; AR: 
autosomal recessive; AD: autosomal dominant. “Red flags” are shown in bold and 
“possible symptoms” are in italic type. 
 
Figure 3. Predominant imaging findings in genetic dystonia-ataxia syndromes 
NBIA: neurodegeneration with brain iron accumulation; BG: basal ganglia. For 
didactic purposes we show only the predominant imaging findings of the diseases 
that can present with dystonia and ataxia that are most representative, either by its 
frequency or its ability to be treatable.  




Table 1: Genetic dystonia-ataxia syndromes 
Table 2. Clinical clues associated with main genetic dystonia-ataxia syndromes.  





Supplementary Table 1: Genetic diseases that may combine dystonia with ataxia. 
Supplementary Table 2. Specific treatment implications 
This article is protected by copyright. All rights reserved.
Table 1: Genetic dystonia-ataxia syndromes 
A) Concomitant dystonia and ataxia 
Spinocerebellar ataxias: SCA-ATN1*; SCA-ATXN2*; SCA-ATXN3* and SCA-TBP*  
Friedreich ataxia (FXN)* 
Ataxia-telangiectasia (ATM)* 
Ataxia with isolated vitamin E deficiency (TTPA)* 
Niemann-Pick disease type C (NPC)* 
Wilson disease (ATP7B)* 
POLG-disorders (POLG)* 
L-2-hydroxyglutaric aciduria (L2HGDH)*  
TUBB4A-disorders (TUBB4A)* 
ATP1A3-disorders (ATP1A3)* 
PLA2G6-associated neurodegeneration (PLA2G6)* 
Glucose transporter type 1 deficiency syndrome (SLC2A1)* 
Ataxia-oculomotor apraxia type 4 (PNKP) 
Autosomal recessive spastic paraplegia type 48 (KIAA0415) 
Autosomal recessive spastic ataxia type 3 (MARS2) 
Autosomal recessive spastic ataxia with hypomyelinating leukodystrophy (NKX6-2) 
Cerebroretinal microangiopathy with calcifications and cysts or Coats plus syndrome (CTC1) 
Childhood-onset neurodegeneration with ataxia, dystonia, and gaze palsy (SQSTM1) 
Birk-Landau-Perez syndrome (SLC30A9) 
Pyruvate dehydrogenase E2 deficiency (DLAT) 
Recessive dystonia-ataxia syndrome due to mitochondrial complex IV deficiency (COX20) 
Mitochondrial complex III deficiency, nuclear type 4 (UQCRQ) 
B) Occasional dystonia-ataxia combination 
Spinocerebellar ataxias: SCA-ATXN1; SCA-SPTBN2; SCA-CACNA1A; SCA-ATXN7; SCA-ATXN8OS; SCA-
ATXN10; SCA-PPP2R2B; SCA-KCNC3; SCA-PRKCG; SCA-KCND3; SCA-AFG3L2; SCA-TGM6; SCA-NOP56 
and SCA/HSP-VAMP1 
Ataxia-oculomotor apraxia type 1 (APTX) and type 2 (SETX) 
Gaucher disease, type III (GBA) 
Chediak-Higashi syndrome (LYST) 
Cockayne syndrome (ERCC) 
Tay-Sachs disease or GM2-gangliosidosis type I (HEXA) 
Biotin-thiamine-responsive basal ganglia disease (SLC19A3) 
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PRRT2-associated disease spectrum (PRRT2) 
Myoclonic epilepsy of Unverricht and Lundborg (CSTB) 
Fatty acid hydroxylase-associated neurodegeneration or autosomal recessive spastic paraplegia-35 (FA2H) 
Neurodegeneration with brain iron accumulation-1 or pantothenate kinase-associated neurodegeneration (PANK2) 
Mitochondrial complex I deficiency (multiple genes) 
Mitochondrial complex III deficiency, nuclear type 2 (TTC19) 
Mitochondrial disorder due to genomic rearrangements affecting the ATAD3 gene 
Mitochondrial DNA depletion syndrome type 13 (FBXL4) 
Combined oxidative phosphorylation deficiency type 29 (TXN2) 
Pyruvate dehydrogenase E1-alpha deficiency (PDHA1) 
Allan-Herndon-Dudley syndrome or monocarboxylate transporter type 8 deficiency  (SLC16A2) 
Sulfocysteinuria or sulfite oxidase deficiency (SUOX) 
Primary coenzyme Q10 deficiency type 4 (ADCK3) 
Autosomal recessive spinocerebellar ataxia type 5 or Galloway-Mowat syndrome (WDR73) 
Autosomal recessive spastic ataxia type 5 (AFG3L2) 
Brain-lung-thyroid syndrome and benign hereditary chorea (NKX2-1) 
Congenital disorder of glycosylation type Ia (PMM2) 
Ataxia-telangiectasia-like disorder-1 (MRE11A) 
Pelizaeus-Merzbacher disease or hypomyelinating leukodystrophy type 1 (PLP1) 
Progressive leukoencephalopathy with ovarian failure (AARS2) 
Progressive encephalopathy with or without lipodystrophy (BSCL2) 
Episodic encephalopathy due to thiamine pyrophosphokinase deficiency (TPK1) 
Limb-girdle muscular dystrophy type 2S (TRAPPC11) 
Juvenile amyotrophic lateral sclerosis-2 (ALS2) 
X-linked spinocerebellar ataxia type 1 (ATP2B3) 
X-linked syndromic mental retardation, Christianson type or Angelman-like syndrome (SLC9A6) 
Kallmann syndrome (KAL1) 
*Most frequent causes of concomitant dystonia and ataxia. 
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Table 2: Clinical clues associated with main genetic dystonia-ataxia syndromes 





Glucose transporter type 1 deficiency syndrome (SLC2A1) 
PLA2G6-associated neurodegeneration (PLA2G6) 
TUBB4A-disorders (TUBB4A) 
L-2-hydroxyglutaric aciduria or academia (L2HGDH) 
Recessive dystonia-ataxia syndrome due to mitochondrial complex IV deficiency 
(COX20) 
Pyruvate dehydrogenase E2 deficiency (DLAT) 
Cognitive decline 
  
Wilson disease (ATP7B) 
Niemann-Pick disease (NPC) 
PLA2G6-associated neurodegeneration (PLA2G6) 
Glucose transporter type 1 deficiency syndrome (SLC2A1) 
Autosomal recessive spastic ataxia type 3 (MARS2) 
Cerebroretinal microangiopathy with calcifications and cysts syndrome (CTC1) 
Childhood-onset neurodegeneration with ataxia, dystonia, and gaze palsy 
(SQSTM1) 
Ataxia-oculomotor apraxia type 4 (PNKP) 
Dentatorubral-pallidoluysian atrophy (ATN1) 
Spinocerebellar ataxia type 17 (TBP) 
Opthalmoparesis 
  
Spinocerebellar ataxia type 1 (ATXN1) 
Spinocerebellar ataxia type 2 (ATXN2) 
Spinocerebellar ataxia type 3 (ATXN3) 
Niemann-Pick disease (NPC) 
Gaucher disease, type III (GBA) 
POLG-disorders (POLG) 





Ataxia-oculomotor apraxia type 1 (APTX) 
Ataxia-oculomotor apraxia type 2 (SETX) 
Ataxia-oculomotor apraxia type 4 (PNKP) 
Gaucher disease, type III (GBA) 
Childhood-onset neurodegeneration with ataxia, dystonia, and gaze palsy 
(SQSTM1) 
Retinopathy Cerebroretinal microangiopathy with calcifications and cysts (CTC1) 
Ataxia with isolated vitamin E deficiency (TTPA) 
Optic atrophy 
  
Friedreich ataxia (FXN) 
PLA2G6-associated neurodegeneration (PLA2G6) 
L-2-hydroxyglutaric aciduria or academia (L2HGDH) 
Cerebroretinal microangiopathy with calcifications and cysts (CTC1) 
ATP1A3-disorders (ATP1A3) 
Abnormal eye Spinocerebellar ataxia type 1 (ATXN1) 




Spinocerebellar ataxia type 2 (ATXN2) 
Spinocerebellar ataxia type 3 (ATXN3) 
Spinocerebellar ataxia type 6 (CACNA1A) 
Friedreich ataxia (FXN) 
PLA2G6-associated neurodegeneration (PLA2G6) 
Seizures Niemann-Pick disease (NPC) 
PLA2G6-associated neurodegeneration (PLA2G6) 
Dentatorubral-pallidoluysian atrophy (ATN1) 
Spinocerebellar ataxia type 17 (TBP) 
TUBB4A-disorders (TUBB4A) 
Glucose transporter type 1 deficiency syndrome (SLC2A1) 




Friedreich ataxia (FXN) 
Ataxia with isolated vitamin E deficiency (TTPA) 
Ataxia-telangiectasia (ATM) 
Ataxia-oculomotor apraxia type 1 (APTX) 
Ataxia-oculomotor apraxia type 2 (SETX) 
Ataxia-oculomotor apraxia type 4 (PNKP) 
PLA2G6-associated neurodegeneration (PLA2G6) 
POLG-disorders (POLG) 
ATP1A3-disorders (ATP1A3) 
Spasticity Spinocerebellar ataxia type 2 (ATXN2) 
Spinocerebellar ataxia type 3 (ATXN3) 
TUBB4A-disorders (TUBB4A) 
Autosomal recessive spastic ataxia type 3 (MARS2) 
Autosomal recessive spastic paraplegia type 48 (KIAA0415) 
Cerebroretinal microangiopathy with calcifications and cysts (CTC1) 
PLA2G6-associated neurodegeneration (PLA2G6) 
Glucose transporter type 1 deficiency syndrome (SLC2A1) 
Niemann-Pick disease (NPC) 
Myoclonus 
  
Wilson disease (ATP7B) 
Ataxia-telangiectasia (ATM) 
Niemann-Pick disease (NPC) 
Dentatorubral-pallidoluysian atrophy (ATN1) 
Glucose transporter type 1 deficiency syndrome (SLC2A1) 
Parkinsonism 
  
Spinocerebellar ataxia type 2 (ATXN2) 
Spinocerebellar ataxia type 3 (ATXN3) 
Spinocerebellar ataxia type 17 (TBP) 
Wilson disease (ATP7B) 
ATP1A3-disorders (ATP1A3) 
PLA2G6-associated neurodegeneration (PLA2G6) 
Childhood-onset neurodegeneration with ataxia, dystonia, and gaze palsy 
(SQSTM1) 
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Chorea 
  
Wilson disease (ATP7B) 
PLA2G6-associated neurodegeneration (PLA2G6) 
Ataxia-telangiectasia (ATM) 
Dentatorubral-pallidoluysian atrophy (ATN1) 
Spinocerebellar ataxia type 17 (TBP) 




Congenital disorder of glycosylation type Ia (PMM2) 
Kallmann syndrome (KAL1) 
Telangiectasias Ataxia-telangiectasia (ATM) 
Macrocephaly Mitochondrial complex I deficiency (multiple genes) 
Anosmia Kallmann syndrome (KAL1) 
Hepatic disease 
  
Niemann-Pick disease (NPC) 
Wilson disease (ATP7B) 
Mitochondrial complex I deficiency (multiple genes)  
 








Wilson disease                                                (AR)
Kayser-Fleischer ring, sunflower cataract, 
pseudolaughter, facetious smile, liver disease, 
tremor, parkinsonism, myoclonus, chorea, behavior 
disorders, cognitive decline, muscle weakness, 
hemolytic anemia
Friedreich ataxia                                             (AR)
Scoliosis, nystagmus, optic atrophy, pes cavus, 
pyramidal signs, hypertrophic cardiomyopathy, 
diabetes, myoclonus
----------------------------------------------------------------------
Ataxia with isolated vitamin E deficiency (AR)




Niemann-Pick disease (type C)        (AR)
Gelastic cataplexy, jaundice, 
hepatosplenomegaly, behavior disorders, 
cognitive impairment, seizures, myoclonus, 
tremor, spasticity
Ataxia telangiectasia                           (AR)
Telangiectasias and other skin problems, 
immunodeficiency, predisposition to 
neoplasia, chorea, myoclonus, tremor, 
diabetes
--------------------------------------------------------------
Ataxia-oculomotor apraxia type 1     AR)
Peripheral neuropathy, ophthalmoparesis, 
chorea, tremor, pes cavus, scoliosis
--------------------------------------------------------------
Ataxia-oculomotor apraxia type 2    (AR)
Peripheral neuropathy, pyramidal signs, 
chorea, head tremor, strabismus
--------------------------------------------------------------
Ataxia-oculomotor apraxia type 4    (AR)
Peripheral neuropathy, cognitive impairment, 
distal muscle weakness and atrophy, chorea
Developmental delay, psychomotor 
regression, mental retardation 
and/or acute/subacute 
encephalopathy with seizures 
No 
PLA2G6 disorders                                         (AR)
Truncal hypotonia followed by spastic 
tetraparesis, parkinsonism, strabismus, optic 
atrophy, nystagmus, tremor, peripheral neuropathy, 
autonomic dysfunction
----------------------------------------------------------------------
TUBB4A disorders                                         (AD)
Pyramidal and bulbar signs, oculogyric crisis, 
truncal hypotonia, tremor, nystagmus, microcephaly, 
short stature
----------------------------------------------------------------------
GLUT1 deficiency syndrome                (AD/AR)
Paroxysmal movements (exercise-induced 
dystonia), acquired microcephaly, spasticity,  
myoclonus, chorea, tremor
----------------------------------------------------------------------
L-2-hydroxyglutaric aciduria                        (AR)
Optic atrophy, spastic tetraparesis, intention tremor, 
action-induced negative myoclonus, pyramidal signs, 
brain tumors
----------------------------------------------------------------------
Biotin-thiamine-responsive BG disease   (AR)
Rigidity, pyramidal signs, supranuclear facial 




Gaucher disease, type 3                    (AR)
Tonic-clonic or myoclonic seizures, 
pancytopenia, hepatosplenomegaly, bone 
affectation, bulbar and pyramidal signs, 
cognitive decline, parkinsonism
ATP1A3 disorders                                         (AD)
Recurrent episodes of hemiparesis, 












SCA-ATXN1 (SCA1)                                        (AD)
Pyramidal signs, muscular weakness and atrophy, 
decreased deep tendon reflexes, loss of proprioception, 
bulbar dysfunction
--------------------------------------------------------------------------
SCA-ATXN2 (SCA2)                                         (AD)
Pyramidal signs, peripheral neuropathy, fasciculations, 
muscle cramps and atrophy, parkinsonism, autonomic 
dysfunction
--------------------------------------------------------------------------
SCA-ATXN3 (SCA3)                                         (AD)
Nystagmus, diplopia, pyramidal signs, peripheral 
neuropathy, fasciculations, muscle cramps and atrophy, 
parkinsonism
--------------------------------------------------------------------------
SCA-CACNA1A (SCA6)                                  (AD)
Diplopia, dizziness, peripheral neuropathy
Peripheral 
neuropathy
SCA-ATN1 (DRPLA)                              (AD)
Myoclonus, seizures, pyramidal signs, cognitive 
impairment, behavior disorders, chorea
Niemann-Pick disease (type C)                (AR)
Isolated spleno- or hepatosplenomegaly, behavior 




POLG disorders                                                  (AR)
Ptosis, peripheral neuropathy, cognitive impairment, 
seizures, hypoacusis, parkinsonism, chorea, myoclonus, 
muscle atrophy
Ataxia with isolated vitamin E deficiency  (AR)




Wilson disease                                                         (AR)
Kayser-Fleischer ring, sunflower cataract, liver 
disease, pseudolaughter, facetious smile, tremor, 
parkinsonism, myoclonus, muscle weakness, hemolytic 
anemia
Friedreich ataxia                                                     (AR)
Proprioceptive loss, scoliosis, nystagmus, optic 








SCA-TBP (SCA17)                                            (AD)
Chorea, parkinsonism, cognitive impairment, behavior 
disorders, seizures, pyramidal signs
Basal ganglia abnormalities
Corpus callosum atrophy 






- Ataxia with isolated vitamin E deficiency
- SLC2A1 disorders
- ATP1A3 disorders
- Tay-Sachs disease  
















- Ataxia with isolated vitamin E deficiency
Dentate nucleus lesions
- Coats plus syndrome
- L-2-hydroxyglutaric aciduria
- Spastic paraplegia type 48
- HSP/NBIA-FA2H
- Galloway-Mowat syndrome
- Biotin-thiamine-responsive BG disease
- Metachromatic leukodystrophy 
- L-2-hydroxyglutaric aciduria 
- HSP/NBIA-FA2H
 - TUBB4A disorders
- Pyruvate dehydrogenase E1-α def.
- Spastic paraplegia type 48







- Type 1: Pelizaeus-Merzbacher disease
- Type 6: TUBB4A disorders
 - Wilson disease
- Wilson disease 
- NBIA/DYT-PANK2
